TABLE 1.

Summary table of the results of DDI studies performed with the reviewed oral oncolytic drugs.

Drug	Effect CYP3A inhibitorsa			Effect CYP3A inducersa
	Strong	Moderate	Weak	Strong	Moderate	Weak
Alectinibb	36% ↑			18.4% ↓
Ceritinib	118.5% ↑ (51–186)	37% ↑		68.5% ↓ (67–70)	43% ↓
Cobimetinib	572% ↑	280.5% ↑ (226–335)	3% ↑	83% ↓	72% ↓	13% ↓
Dabrafenib	71% ↑			34% ↓
• Hydroxy-dabrafenib	82% ↑			30% ↓
• Desmethyl-dabrafenib	68% ↑			73% ↑
• Carboxy-dabrafenib	16% ↓
Everolimus	1,430% ↑	220% ↑ (74–340)		63% ↓
Imatinib	18.5% ↑ (−3.1–40.1)			73.3% ↓ (72.5–74)		37.1% ↓ (30.2–44)
• N-desmethyl-imatinib	16.75% ↑ (−5–38.5)			10.8% ↓ (9.8–11.7)		4.1% ↑
Lenvatinib	14.5% ↑			6.2% ↑ (−18.2–30.6)
Olaparib	161% ↑ (152–170)	115% ↑ (98–126)	1.5% ↑ (1–2)	79% ↓ (71–87)	57.3% ↓ (53–60)	0%↓
Osimertinib	24.2% ↑			78.5% ↓	42% ↓	0%↓
Palbociclib	86.8% ↑	40% ↑ (38–42)	0.4% ↑ (0.3–0.4)	85.2% ↓	35% ↓ (32–38)
Sonidegib	122.8% ↑ (42–253)	98% ↑ (36–179)		76.6% ↓ (66–88)	49% ↓ (29–65)
Sunitinibc	51% ↑	11% ↑		46% ↓

^aReported as percentage of AUC change, if multiple DDI studies were performed the mean AUC change and range are reported.

^bSum of alectinib and M4.

^cSum of sunitinib and SU12662, except for the moderate inhibitor.